AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Lunai Bioworks Inc.

$2.38 -$5.39 (-69.37%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$2.44
Day Range
$2.31$2.52
Year Range
$1.21$17.52
Market Cap
10.79M
AVG Volume
860.04K
Trailing/Forward PE
-0.04/-
PEG ratio
0
Dividend Yield
-
Next Earnings Date
2026-09-28
Primary Exchange
NASDAQUS
Revenue (USD)
010K20K30K23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
LNAI Revenue (USD) by quarter
PeriodRevenue (USD)
25 Q320.94K
25 Q20
25 Q10
24 Q40
24 Q30
24 Q20
24 Q10
23 Q40
23 Q30
23 Q20
Net Income (USD)
-150M-100M-50M050M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
LNAI Net Income (USD) by quarter
PeriodNet Income (USD)
25 Q3-2.57M
25 Q2-1.8M
25 Q12.82M
24 Q4-126.73M
24 Q3189.18K
24 Q2-7.25M
24 Q1-44.21M
23 Q4-49.92M
23 Q3-58.99M
23 Q2-4.53M
Operating Income (USD)
-60M-40M-20M023 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
LNAI Operating Income (USD) by quarter
PeriodOperating Income (USD)
25 Q3-1.43M
25 Q2-1.82M
25 Q1-2.48M
24 Q4-4.11M
24 Q3-4.16M
24 Q2-4.55M
24 Q1-53.34M
23 Q4-51.29M
23 Q3-8.77M
23 Q2-4.27M
EBITDA (USD)
-150M-100M-50M050M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
LNAI EBITDA (USD) by quarter
PeriodEBITDA (USD)
25 Q3-2.45M
25 Q2-1.67M
25 Q13.05M
24 Q4-126.51M
24 Q3409.84K
24 Q2-7.1M
24 Q1-43.93M
23 Q4-48.21M
23 Q3-58.66M
23 Q2-4.22M
Cash Flows (USD)
-4M-3M-2M-1M023 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
LNAI Cash Flows (USD) by quarter
PeriodCash Flows (USD)
25 Q3-1.03M
25 Q2-1.07M
25 Q1-1.35M
24 Q4-1.81M
24 Q3-1.49M
24 Q2-2.56M
24 Q1-2.02M
23 Q4-2.44M
23 Q3-2.64M
23 Q2-3.19M
EPS (USD)
-80-60-40-2002023 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
LNAI EPS (USD) by quarter
PeriodEPS (USD)
25 Q3-0.8
25 Q2-0.61
25 Q11.04
24 Q4-60.88
24 Q30.09
24 Q2-3.2
24 Q1-22.4
23 Q4-31.04
23 Q3-43.2
23 Q2-5.52
Expenses (USD)
-2.5M02.5M5M7.5M10MR&DSG&ACapex23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
LNAI Expenses (USD) by quarter
PeriodExpenses (USD)
25 Q31.44M
25 Q21.81M
25 Q12.43M
24 Q44.08M
24 Q34.13M
24 Q24.51M
24 Q15.69M
23 Q45.46M
23 Q38.74M
23 Q24.28M
Cash & Debt (USD)
02.5M5M7.5M10MCashLong Term DebtShort Term Debt23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
LNAI Cash & Debt (USD) by quarter
PeriodCash & Debt (USD)
25 Q33.16M
25 Q2491.64K
25 Q1624.81K
24 Q4480.55K
24 Q31.63M
24 Q2311.76K
24 Q1220.57K
23 Q4220.47K
23 Q3312.7K
23 Q2243.98K
Debt ratios
-0.06-0.04-0.0200.0224 Q124 Q224 Q324 Q425 Q125 Q225 Q3
LNAI Debt ratios by quarter
PeriodDebt ratios
25 Q30.01
25 Q2-0.02
25 Q1-0.02
24 Q4-0.05
24 Q3-0.05
24 Q2-0.04
24 Q1-0.02
Margins
0%20%40%60%25 Q3
LNAI Margins by quarter
PeriodMargins
25 Q347.47%
Return on Capital
-200%0%200%400%600%23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
LNAI Return on Capital by quarter
PeriodReturn on Capital
25 Q326.92%
25 Q213.28%
25 Q1-21.62%
24 Q4593.6%
24 Q30.21%
24 Q2-8.84%
24 Q1-45.07%
23 Q4-37.83%
23 Q3-43.89%
23 Q2-10.39%
Shares Outstanding
01M2M3M4M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
LNAI Shares Outstanding by quarter
PeriodShares Outstanding
25 Q33.12M
25 Q22.94M
25 Q12.82M
24 Q42.08M
24 Q32.03M
24 Q22.02M
24 Q12M
23 Q41.61M
23 Q31.37M
23 Q2823.16K
Book Value Per Share (USD)
-5005010023 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
LNAI Book Value Per Share (USD) by quarter
PeriodBook Value Per Share (USD)
25 Q3-3.06
25 Q2-4.62
25 Q1-4.63
24 Q4-10.25
24 Q343.56
24 Q240.57
24 Q149.05
23 Q482
23 Q398.42
23 Q252.96
Total Assets (USD)
050M100M150M200M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
LNAI Total Assets (USD) by quarter
PeriodTotal Assets (USD)
25 Q39.86M
25 Q26.67M
25 Q16.96M
24 Q48.23M
24 Q3117.73M
24 Q2111.34M
24 Q1121.83M
23 Q4163.13M
23 Q3178.09M
23 Q258.02M
Free Cash Flow Yield
-150%-100%-50%0%med -53.47%Oct 25Dec 25Jan 26Mar 26May 26Jul 26Sep 26
LNAI Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-70.73%
Sep 26-70.44%
Aug 26-71.03%
Aug 26-78.3%
Aug 26-75.83%
Aug 26-69.85%
Jul 26-86.78%
Jul 26-72.25%
Jul 26-59.7%
Jul 26-57.26%
Jul 26-52.61%
Jun 26-52.44%
Jun 26-44.54%
Jun 26-69.85%
Jun 26-68.71%
May 26-63.27%
May 26-86.23%
May 26-94.6%
May 26-73.82%
May 26-76.12%
Apr 26-78.58%
Apr 26-69.85%
Apr 26-65.61%
Apr 26-65.39%
Mar 26-59.05%
Mar 26-51.97%
Mar 26-131.67%
Mar 26-104.77%
Feb 26-86.5%
Feb 26-58.72%
Feb 26-43.54%
Feb 26-48.31%
Jan 26-41.03%
Jan 26-36.47%
Jan 26-34.6%
Jan 26-33.34%
Jan 26-32.95%
Dec 25-32.95%
Dec 25-30.48%
Dec 25-29.91%
Dec 25-25.6%
Nov 25-40.06%
Nov 25-38.12%
Nov 25-44.59%
Nov 25-50.69%
Oct 25-54.33%
Oct 25-43.77%
Oct 25-39.39%
Oct 25-41.83%
Oct 25-36.64%
Sep 25-36.36%
Sep 25-27.01%
Sep 25-23.75%
Sep 25-22.83%
Price to Sales
200300400500600med 359.54Jun 26Jul 26Jul 26Aug 26Sep 26
LNAI Price to Sales by quarter
PeriodPrice to Sales
Sep 26355.07
Sep 26356.56
Aug 26353.57
Aug 26320.75
Aug 26331.2
Aug 26359.54
Jul 26289.42
Jul 26347.61
Jul 26420.71
Jul 26438.61
Jul 26477.4
Jun 26478.89
Jun 26563.93
Jun 26359.54
Jun 26365.51
Lunai Bioworks Inc.
LNAI
Stockpicker

Video analysis: LNAI

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: LNAI

Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint

prnewswire.com · 4 Sep 2026

Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint

Correction Updates a Reference Link; No Other Content in the Original Release Has Changed WILMINGTON, Del. and SACRAMENTO, Calif.

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

prnewswire.com · 27 Aug 2026

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5 WILMINGTON, Del. and SACRAMENTO, Calif.

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027

prnewswire.com · 4 Aug 2026

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027

New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and pharmaceutical partnering. SACRAMENTO, Calif.

Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit

prnewswire.com · 4 Aug 2026

Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit

Amended Complaint Alleges 29.6 Million Failed to Deliver Shares and Single Day Trading Volume of 15.3 Times Shares Outstanding, Company Seeks Treble Damages Under Federal RICO Statute WILMINGTON, Del. and SACRAMENTO, Calif.

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

prnewswire.com · 17 Jun 2026

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ -- Fellow Shareholders, Over the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to execute its strategy of building a next-generation biotechnology company at the intersection of artificial intelligence, and national security and biology.

Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session

feeds.benzinga.com · 17 Jun 2026

Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session

Lunai Bioworks Inc. shares soared 80.88% after-hours after regaining Nasdaq compliance with minimum bid price requirements.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.